A Case of Mantle Cell Lymphoma Treated with Autologous Stem Cell Transplantation and Rituximab / 대한혈액학회지
Korean Journal of Hematology
;
: 215-219, 2006.
Artigo
em Coreano
| WPRIM
| ID: wpr-720717
ABSTRACT
Mantle cell lymphoma is a subtype of aggressive non-Hodgkin's lymphoma and usually presents in advanced stages. When treated with a regimen such as CHOP, the median survival is about three years. More aggressive front-line therapy with the hyper-CVAD regimen or high-dose therapy with stem cell support has shown encouraging results in several trials. The addition of rituximab to the chemotherapy regimens, or high-dose therapy, increased the response and survival rates in patients with mantle cell lymphoma. We report a case of mantle cell lymphoma that was successfully treated with aggressive front-line treatment strategies. The patient achieved complete remission with initial hyper-CVAD regimen, and was consolidated with autologous stem cell transplantation and subsequent rituximab.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Células-Tronco
/
Linfoma não Hodgkin
/
Taxa de Sobrevida
/
Linfoma de Célula do Manto
/
Transplante de Células-Tronco
/
Tratamento Farmacológico
/
Rituximab
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Hematology
Ano de publicação:
2006
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS